PGEN at a glance
PRECIGEN, INC. (PGEN, SEC CIK 1356090) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PRECIGEN, INC. (PGEN) reported revenue of $9.7 million (up 146.7% from FY2024) and a net loss of $250.6 million. Diluted EPS was -$1.37.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding PRECIGEN, INC. (PGEN) shares worth $469.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by KINDLER JEFFREY B on August 26, 2026 of 185,000 shares at $7.44 per share.
- In the last 90 days, PGEN insiders reported 0 open-market purchases ($0) and 3 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.7M
- +146.7% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$2.1M
- 13F holders
- 26 funds
- $469.4M · +0 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $74.1M, up >200% YoY from $2.9M, driven by Papzimeos product revenue of $72.9M
- Operating margin 52.1% vs (1,180.4)% YoY, with operating income $38.7M vs loss of $34.5M
- Papzimeos strongest product line, $72.9M revenue; collaboration and licensing revenue weakest, $0 vs $1.8M YoY
- Q3 operating cash flow $11.9M positive; September 30 cash $15.0M plus investments of $36.0M
- Outlook: continued Papzimeos commercialization, with headwinds from 127-day customer payment terms and potential additional capital needs
Risk Factors
- No additional material risk-factor changes since the Annual Report
- Carried-forward risks may materially affect operating results
- Carried-forward risks may materially affect financial condition
- SEC filings contain additional relevant risk disclosures
AI summary of the PGEN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 announces Precigen’s financial results for the quarter ended September 30, 2026
- Investor focus: quarterly performance metrics, cash position and management commentary in the attached earnings release
Item EX-99.1: Item EX-99.1
- Q3 2026 PAPZIMEOS revenue $72.9M, up 37% sequentially, confirming accelerating commercial adoption
- Positive operating cash flow $11.9M, one quarter ahead of guidance, reducing near-term financing pressure
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 contains Precigen’s financial results for the quarter ended June 30, 2026
- August 4, 2026 press release provides the substantive earnings details
Item EX-99.1: Item EX-99.1
- PAPZIMEOS revenue reached $53.1 million in Q2, more than doubling from the prior quarter and driving quarterly net income of $20.1 million
- Total revenue rose to $55.0 million from $0.9 million, while operating income reached $22.6 million versus a $31.8 million loss
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved 7 million additional shares under Precigen’s 2023 Omnibus Incentive Plan
- Expanded equity capacity supports future employee and executive compensation
Item 5.07: Submission of Matters to a Vote of Security Holders
- All nine director nominees elected for one-year terms, preserving board continuity
- Vinita Gupta faced strongest opposition, with 57,856,824 votes against
AI summaries of PGEN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PGEN
Don't miss the next PGEN filing
- Alerts as it files. A push when PGEN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PGEN, by share count.
- Ask anything. An AI agent that reads every PGEN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Thomasian Harry Jr. | M | Sep 23, 2026 | 10,744 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 1 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 2 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 42,918 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 42,918 | $2.33 |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 10,744 | $4.72 |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 1 | $1.21 |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 2 | $0.96 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.9M | $9.7M |
| Operating Income | -$99.8M | -$135.0M | -$110.5M |
| Net Income | -$95.9M | -$126.2M | -$250.6M |
| Op. Margin | - | -3440.2% | -1141.1% |
| Net Margin | - | -3216.2% | -2588.2% |
| Balance Sheet | |||
| Total Assets | - | $145.3M | $155.5M |
| Equity | - | $38.5M | $20.9M |
| ROE | - | -327.8% | -1198.6% |
| Per Share | |||
| EPS | - | $-0.47 | $-1.37 |
| Cash Flow | |||
| Operating CF | -$66.9M | -$68.2M | -$87.8M |
| CapEx | $1.5M | $8.6M | $2.0M |
Source: XBRL data in PRECIGEN, INC. (PGEN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PGEN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $469.4M |
| Q2 2026 | 26 | $334.7M |
| Q1 2026 | 23 | $209.2M |
| Q4 2025 | 20 | $236.6M |
| Q3 2025 | 23 | $130.5M |
| Q2 2025 | 23 | $44.3M |
| Q1 2025 | 23 | $26.2M |
| Q4 2024 | 18 | $16.9M |
- Prudential Financial+1.28M (+829%)
- Citadel Advisors LLC+733.2K (+89%)
- Morgan Stanley+662.1K (+19%)
- Invesco Ltd+190.1K (+127%)
- AQR Capital Management+143.4K (+98%)
- Goldman Sachs Group−1.93M (-57%)
- State Street Corp−1.28M (-11%)
- Citigroup−413.0K (-57%)
- Bank of America Corp−360.8K (-20%)
- Franklin Resources−345.1K (-34%)
- FMR LLC (Fidelity)−2.57M
Source: 13F-HR filings on SEC EDGAR (aggregated from 182 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PGEN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 27, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PGEN SEC filings: frequently asked questions
Are PGEN insiders buying or selling?
In the last 90 days, PRECIGEN, INC. (PGEN) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $2.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PGEN stock?
As of September 30, 2026, the largest PRECIGEN, INC. (PGEN) holders among the 13F filers tracked by SignalX were BlackRock ($147.9 million), State Street Corp ($91.8 million), Vanguard Capital Management LLC ($68.6 million), Morgan Stanley ($35.4 million), Vanguard Portfolio Management LLC ($19.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PGEN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PRECIGEN, INC. (PGEN) reported revenue of $9.7 million (up 146.7% from FY2024) and a net loss of $250.6 million. Diluted EPS was -$1.37. The figures come from the XBRL data in the 10-K.
What did PGEN report in its latest 8-K?
PRECIGEN, INC. (PGEN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 announces Precigen’s financial results for the quarter ended September 30, 2026.
What are the latest PGEN SEC filings?
PRECIGEN, INC. (PGEN) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 24, 2026.
What is PGEN's SEC CIK number?
PRECIGEN, INC. (PGEN)'s SEC Central Index Key (CIK) is 1356090. EDGAR lists every PGEN filing under that number.
Ask anything about PGEN
The research agent reads PGEN's filings, financials, insider trades and 13F holders, then answers with sources.